Tag - alzheimers

 
 

ALZHEIMERS

Lecanemab was developed by drugmakers Eisai of Japan and Biogen of the United States.
JAPAN / Science & Health
Nov 15, 2024
European agency switches to recommending new Alzheimer's drug
The committee judged that the efficacy of lecanemab outweighs the risk for some patients.
For patients using donanemab, it will cost them about ¥3.08 million per year. But national insurance coverage will have the government shoulder most of the cost.
JAPAN / Science & Health
Nov 13, 2024
Japan OKs insurance coverage of Alzheimer's drug donanemab
Donanemab became the second Alzheimer's drug that targets causative deposited plaque in the brain to win the coverage after lecanemab.
A scientist looks at brain scans of a patient suffering from Alzheimer's disease in Geneva in 2023.
WORLD / Science & Health
Sep 21, 2024
Revolution or mirage? Controversy surrounds new Alzheimer's drugs
For defenders, the drugs represent a real chance to fight the disease. For detractors, they are a disappointment after a long line of costly failures.
U.K. authorities have approved lecanemab, a novel Alzheimer's drug developed by Eisai, making Britain the first country in Europe to greenlight the drug.
JAPAN
Aug 23, 2024
Britain OKs Eisai's novel Alzheimer's drug lecanemab
The United Kingdom is the first country in Europe to greenlight the drug.
A health ministry panel has approved Eli Lilly's donanemab drug for Alzheimer's patients.
JAPAN / Science & Health
Aug 2, 2024
Japan's health ministry set to approve second Alzheimer's drug
Donanemab, developed by U.S. pharmaceutical firm Eli Lilly, has been backed by a ministry panel.
A scientist looks at scans at the Memory Center at the Department of Readaptation and Geriatrics of the University Hospital in Geneva on June 6, 2023.
WORLD / Science & Health
Jul 29, 2024
A blood test accurately diagnosed Alzheimer’s 90% of the time, study finds
A team of researchers reported that a blood test was significantly more accurate than doctors’ interpretation of cognitive tests and CT scans in signaling Alzheimer's.
The latest research indicates that heat stress is likely to worsen the condition of people with Alzheimer’s disease — which accounts for over half of all dementia cases in Japan — by making them more irritated or exacerbating their cognitive decline.
JAPAN / Science & Health / Boiling Point
Jul 29, 2024
For aging Japan, a troubling link between heat and dementia
The latest research indicates that heat can exacerbate cognitive decline and worsen dementia symptoms.
Leqembi, which was developed by U.S. multinational Biogen and Japanese-based Eisai, is the brand name of an active substance called lecanemab, which is used to treat adults with mild memory and cognitive problems resulting from the early stages of the common type of dementia.
JAPAN / Science & Health
Jul 27, 2024
European medicines watchdog rejects Eisai's new Alzheimer's drug
The watchdog said the risks of side effects, including potential brain bleeding, outweighed the benefits.
Researchers at Tokyo's Juntendo University investigated whether an SGLT2 inhibitor, a drug that promotes sugar excretion through urine, could remove aging cells by administering it to obese mice for a week.
JAPAN / Science & Health
May 31, 2024
Diabetes drug shows promise for aging-related illnesses in mice study
The Juntendo University study shows an SGLT2 inhibitor successfully eliminating senescent cells, which accumulate with age, in the mice's visceral fat.
The latest findings by University of Tokyo researchers raise hopes that the disease may be treated if doctors can identify people who will develop Alzheimer’s before its onset.
JAPAN / Science & Health
May 23, 2024
Japanese researchers confirm blood test predicts risk of Alzheimer's
The latest study raises hopes that if doctors can identify who might be at risk of developing Alzheimer’s beforehand, it could be treated early.
The latest figure is significantly less than a previous projection released in 2015 that said more than 8 million people would have dementia by 2040.
JAPAN / Science & Health
May 8, 2024
Nearly 6 million elderly people in Japan will have dementia by 2040
While the figure is lower than a previous projection, the latest estimate still showed a steady growth in the number of people with dementia.
Tests for patients suffering from Alzheimer's disease. According to the Alzheimer's Association, the disease is estimated to affect more than 6 million Americans.
WORLD / Science & Health / FOCUS
Apr 24, 2024
Alzheimer's drug adoption in U.S. slowed by doctors' skepticism
There is an entrenched belief among some doctors that treating the memory-robbing disease is futile.
Alzheimer's drug lecanemab. A new trial is the world's first to combine lecanemab with a different drug.
JAPAN / Science & Health
Mar 15, 2024
Japan starts clinical trial of familial Alzheimer's treatment
The clinical trial is under way in 16 countries, with four people in their 30s to 50s participating in Japan.
Eisai's Alzheimer's drug Leqembi
BUSINESS / Companies
Feb 5, 2024
Eisai sees 'huge' growth potential for Alzheimer's drug in China
The Japanese pharmaceutical firm aims to roll out its groundbreaking Alzheimer’s drug Leqembi to 1,500 people in China later this year.
Shitsui Hakoishi, 107, works with researcher Yasumichi Arai (left) while her younger brother, Hidemasa, looks on. Researchers like Arai believe the healthy and active Hakoishi's cells may hold the secret to living a long life.
JAPAN / Science & Health / Longform
Jan 27, 2024
Living until 100, if not forever, in good health
Immortality may be out of reach, but can a slew of research projects prolong our natural aging process?
An elderly person plays a racing video game in 2022 to ward off dementia.
JAPAN / Science & Health
Sep 25, 2023
As Japan OKs Alzheimer's drug, issue of side effects comes into focus
There are big challenges ahead for the use of lecanemab, particularly on how to control side effects such as brain swelling and bleeding.
Shinobu Yamanaka, a mom of three sons and director of a day care facility in Konan, Kochi Prefecture, serves up to eight "members" six days a week.
JAPAN / Science & Health / FOCUS
Aug 22, 2023
Kochi dementia care center aims to set new paradigm in Japan
A new generation of people with Alzheimer’s in Japan are trying to change not only dementia care but also social attitudes toward patients.
Packages of lecanemab, marketed as Leqembi, for the U.S. market
JAPAN / Science & Health
Aug 21, 2023
Japanese ministry panel gives OK to Alzheimer’s drug lecanemab
The panel’s endorsement will be followed by official approval by the health minister in coming days.
Japan Times
WORLD / Science & Health
Jul 17, 2023
Alzheimer's diagnosis revamp embraces rating scale similar to cancer
New guidelines would replace terminology such as mild, moderate and severe, instead using a numerical system related to disease progression.
Japan Times
BUSINESS / Companies
Jul 11, 2023
Eisai appoints CEO’s son to lead global Alzheimer drug program
Eisai's former global Alzheimer drug program officer, who led the push for U.S. approval of breakthrough medicine Leqembi, will retire at the end of the month.

Longform

Construction takes place on the Takanawa Gateway Convention Center in Tokyo, slated to open in 2025.
A boom for business tourism in Japan?